DBV Technologies SA

DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document

11 أبريل 2025 16:30:00 بحسب Nasdaq GlobeNewswire

DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved

27 مارس 2025 22:30:05 بحسب Nasdaq GlobeNewswire

DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results...

24 مارس 2025 02:30:00 بحسب Nasdaq GlobeNewswire

DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress

25 فبراير 2025 16:01:00 بحسب Nasdaq GlobeNewswire

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

13 يناير 2025 16:05:00 بحسب Nasdaq GlobeNewswire

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study

08 يناير 2025 16:05:00 بحسب Nasdaq GlobeNewswire

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

11 ديسمبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Information regarding the total number of voting rights and  total number of shares of the Company as of November 30, 2024

02 ديسمبر 2024 16:30:00 بحسب Nasdaq GlobeNewswire

DBV Technologies Announces Plan to Implement ADS Ratio Change

11 نوفمبر 2024 16:30:00 بحسب Nasdaq GlobeNewswire

DBV Technologies Reports Third Quarter 2024 Financial Results

06 نوفمبر 2024 16:30:00 بحسب Nasdaq GlobeNewswire

DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe

22 أكتوبر 2024 16:45:00 بحسب Nasdaq GlobeNewswire

DBV Technologies to Participate in Upcoming ACAAI 2024 Congress

18 أكتوبر 2024 16:30:00 بحسب Nasdaq GlobeNewswire

Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024

14 أكتوبر 2024 16:30:00 بحسب Nasdaq GlobeNewswire

DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial

23 سبتمبر 2024 16:30:00 بحسب Nasdaq GlobeNewswire

DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

04 سبتمبر 2024 16:30:00 بحسب Nasdaq GlobeNewswire

Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024

02 أغسطس 2024 16:30:00 بحسب Nasdaq GlobeNewswire

DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report

30 يوليو 2024 17:30:00 بحسب Nasdaq GlobeNewswire

DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results

30 يوليو 2024 16:30:00 بحسب Nasdaq GlobeNewswire

DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024

29 يوليو 2024 01:30:00 بحسب Nasdaq GlobeNewswire

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

08 يوليو 2024 16:30:00 بحسب Nasdaq GlobeNewswire